Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
| Autor: | Pilar García-Alfonso, Jesús García-Foncillas, Ramon Salazar, Stefania Landolfi, Samuel Navarro, Pedro Pérez-Segura, Rocio Garcia-Carbonero, E. Musulén-Palet, Miriam Cuatrecasas, S. Ramón y Cajal |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Neuroblastoma RAS viral oncogene homolog Cancer Research medicine.medical_specialty Pathology Colorectal cancer EGFR MEDLINE NRAS Medical Oncology medicine.disease_cause Polymerase Chain Reaction GTP Phosphohydrolases Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins Internal medicine Health care KRAS Biomarkers Tumor medicine Humans Colorectal carcinomas Societies Medical Receptor del factor de crecimiento epidérmico Epidermal growth factor receptor business.industry Membrane Proteins General Medicine Therapeutic decision making medicine.disease Expert group CRC ErbB Receptors Biomarcadores Spain ras Proteins Biomarker (medicine) Colorectal Neoplasms business Biomarkers Carcinoma colorrectal |
| Zdroj: | CLINICAL & TRANSLATIONAL ONCOLOGY r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname Digital.CSIC. Repositorio Institucional del CSIC |
| ISSN: | 1699-3055 1699-048X |
| DOI: | 10.1007/s12094-014-1252-0 |
| Popis: | Revisión © 2014 SEAP y SEC. The publication of this consensus statement is a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM), which aims to revise and update the diagnostic and treatment recommendations published two years ago on biomarker use and the management of patients with colorectal carcinoma, with the intention of improving healthcare efficiency and use of resources. This group of experts recommends testing for KRAS and NRAS status in all patients with metastatic colorectal carcinoma being considered for anti-epidermal growth factor receptor (anti-. EGFR) therapy, as this type of treatment should only be used in patients not harbouring mutations in these genes. In contrast, testing for BRAF, EGFR, PI3K and PTEN mutation status is not necessary for therapeutic decision-making and therefore does not need to be done routinely. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink